TP53 and central nervous system cancer: In addition to the vulnerability of TP53-mutant glioma cells to ATM/CHK1 inhibitors, Werbrouck et al. identified a synthetic lethal interaction between RT and knockdown of the checkpoint kinases WEE1 and polo-like kinase 1 (PLK1) in TP53-mutant H3-K27M cells (25).